ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis

Zhang, Yu-Sheng; Zheng, Yan-Dan; Yuan, Yan; Chen, Shi-Chun*; Xie, Bao-Cheng*佛山市第一人民医院; 南方医科大学
Frontiers in Endocrinology2021-10-14DOI: 10.3389/fendo.2021.735824
39被引9阅读
引用收藏
分享

摘要

Purpose:& nbsp;Available data on the effects of anti-diabetic drugs on fracture risk are contradictory. Therefore, our study aimed to analyze all available data on the effects of anti-diabetic drugs on fracture risk in type 2 diabetes mellitus (T2DM) patients. @@@ @@@ Methods:& nbsp;Embase, Medline, ClinicalTrials.gov, and Cochrane CENTRAL were searched for relevant trials. All data analyses were performed with STATA (12.0) and R language (3.6.0). Risk ratio (RR) with its 95% confidence interval (CI) was calculated by combining data for the fracture effects of anti-diabetic drugs, including sodium-glucose co-transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, a-glucosidase inhibitors, thiazolidinediones, biguanides, insulin, and sulfonylureas. @@@ @@@ Results:& nbsp;One hundred seventeen eligible randomized controlled trials (RCTs) with 221,364 participants were included in this study. Compared with placebo, trelagliptin (RR 3.51; 1.58-13.70) increased the risk of fracture, whereas albiglutide (RR 0.29; 0.04-0.93) and voglibose (RR 0.03; 0-0.11) decreased the risk of fracture. Other medications were comparable in terms of their effects on fracture risk, and no statistical significance was observed. In terms of fractures, voglibose (0.01%) may be the safest option, and trelagliptin (13.64%) may be the worst. Sensitivity analysis results were consistent with those of the main analysis. No statistically significant differences were observed in the regression coefficients of age (1.03; 0.32-2.1), follow-up duration (0.79; 0.27-1.64), and sex distribution (0.63; 0.15-1.56). @@@ @@@ Conclusions:& nbsp;We found varied results on the association between the use of anti-diabetic drugs and fracture risk. Specifically, trelagliptin raised the risk of fracture, whereas voglibose and albiglutide showed benefit with statistical difference. Other drugs were comparable in terms of their effects on fracture risk. Some drugs (omarigliptin, sitagliptin, vildagliptin, saxagliptin, empagliflozin, ertugliflozin, rosiglitazone, pioglitazone, and nateglinide) may increase the risk of fracture, while others (such as dulaglutide, exenatide, liraglutide, semaglutide, lixisenatide, linagliptin, alogliptin, canagliflozin, dapagliflozin, glipizide, gliclazide, glibenclamide, glimepiride, metformin, and insulin) may show benefits. The risk of fracture was independent of age, sex distribution, and the duration of exposure to anti-diabetic drugs. When developing individualized treatment strategies, the clinical efficacy of anti-diabetic drugs must be weighed against their benefits and risks brought about by individual differences of patients. @@@ @@@ Systematic Review Registration:& nbsp;This Systematic Review was prospectively registered on the PROSPERO (https://www.crd.york.ac.uk/PROSPERO/, registration number CRD42020189464).

学科与关键词

关键词
anti-diabetic drugfracturetype 2 diabetes mellitussystematic reviewmeta-analysis
相关
加载中…
  • The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
    Xie, Baocheng; Chen, Shichun; Xu, Yongxiang; Han, Weichao; Hu, Runkai; Chen, Minyi; Zhang, Yusheng*; Ding, Shaobo*Frontiers in Pharmacology, 2021, 12: 697442.被引 19
  • Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
    Zhou, Jiandong; Liu, Xuejin; Chou, Oscar Hou-In; Li, Lifang; Lee, Sharen; Wong, Wing Tak; Zhang, Qingpeng; Chang, Carlin; Liu, Tong; Tse, Gary; Jing, Fengshi*; Cheung, Bernard Man Yung*RHEUMATOLOGY, 2023, 62(4): 1501-1510.被引 12
  • Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway
    Cheng, Yanzhen; Liu, Peng; Xiang, Qianru; Liang, Jiamin; Chen, Huafeng; Zhang, Hua*; Yang, Li*BMC MUSCULOSKELETAL DISORDERS, 2022, 23(1): 465.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2021-10-14
卷期
第 12 卷
页码
735824
DOI
10.3389/fendo.2021.735824
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82000842]; Guangdong Basic and Applied Basic Research Foundation [2021A1515010151]; Project of Administration of Traditional Chinese Medicine of Guangdong Province of China [20211403]; Medical Scientific Research Foundation of Guangdong Province of China [B2020086]; Dongguan Science and Technology of Social Development Program [202050715001197]

作者

  • Z

    Zhang, Yu-Sheng (第一作者)

    first peoples hosp foshan

  • Z

    Zheng, Yan-Dan

    first peoples hosp foshan

查看全部 5 位作者收起作者
  • Y

    Yuan, Yan

    first peoples hosp foshan

  • C

    Chen, Shi-Chun (通讯)

    southern med univ

  • X

    Xie, Bao-Cheng (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417